Post-earnings recap
Reported
Wed, Oct 27, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
Boston Scientific's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by 1.33%, likely due to the lack of revenue details and guidance, which may have left investors uncertain about future performance. The cautious tone from management suggests they are focused on long-term growth despite current market challenges.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.41 | N/A | +3.27% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, no specific revenue guidance was provided.
We are pleased with our EPS performance this quarter.
Our focus remains on innovation and growth in key markets.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—